Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

Core Viewpoint - Indivior PLC has appointed Joe Ciaffoni as the new Chief Executive Officer, effective upon shareholder approval of a new remuneration policy at the AGM in May 2025 [1][4]. Company Leadership Changes - Joe Ciaffoni, previously an Independent Non-Executive Director since December 2024, has over 30 years of experience in the pharmaceuticals and biotech sectors, including roles at Collegium Pharmaceutical, Endo International, Biogen, and Shionogi Inc. [2] - Mark Crossley will step down as CEO and Board Director after a successful tenure, remaining with the company to support the transition until at least the AGM in May 2025 [3][5]. Company Vision and Mission - Indivior is focused on developing medicines for substance use disorders (SUD) and aims to transform SUD from a global crisis into a recognized chronic disease, ensuring access to evidence-based treatment for all patients [7]. - The company has a global portfolio of opioid use disorder (OUD) treatments and is expanding its pipeline of product candidates in this category [7]. Board Statements - David Wheadon, Chair of Indivior's Board, expressed confidence in Ciaffoni's leadership to drive the next stage of growth and deliver on the company's potential [4]. - Mark Crossley reflected on his decade-long commitment to Indivior, emphasizing the company's role in addressing substance use disorders [6].